Logo image of GLMD

GALMED PHARMACEUTICALS LTD (GLMD) Stock Fundamental Analysis

USA - NASDAQ:GLMD - IL0011313900 - Common Stock

1.35 USD
-0.12 (-8.16%)
Last: 10/29/2025, 4:43:41 PM
1.3882 USD
+0.04 (+2.83%)
After Hours: 10/29/2025, 4:43:41 PM
Fundamental Rating

2

Taking everything into account, GLMD scores 2 out of 10 in our fundamental rating. GLMD was compared to 534 industry peers in the Biotechnology industry. The financial health of GLMD is average, but there are quite some concerns on its profitability. GLMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GLMD had negative earnings in the past year.
GLMD had a negative operating cash flow in the past year.
GLMD had negative earnings in each of the past 5 years.
GLMD had a negative operating cash flow in each of the past 5 years.
GLMD Yearly Net Income VS EBIT VS OCF VS FCFGLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

GLMD has a better Return On Assets (-38.01%) than 61.42% of its industry peers.
GLMD has a Return On Equity of -42.50%. This is in the better half of the industry: GLMD outperforms 70.04% of its industry peers.
Industry RankSector Rank
ROA -38.01%
ROE -42.5%
ROIC N/A
ROA(3y)-63.37%
ROA(5y)-66.75%
ROE(3y)-76.34%
ROE(5y)-80.13%
ROIC(3y)N/A
ROIC(5y)N/A
GLMD Yearly ROA, ROE, ROICGLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLMD Yearly Profit, Operating, Gross MarginsGLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

GLMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GLMD has more shares outstanding
There is no outstanding debt for GLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLMD Yearly Shares OutstandingGLMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
GLMD Yearly Total Debt VS Total AssetsGLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

GLMD has an Altman-Z score of -10.49. This is a bad value and indicates that GLMD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.49, GLMD is doing worse than 73.78% of the companies in the same industry.
There is no outstanding debt for GLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.49
ROIC/WACCN/A
WACCN/A
GLMD Yearly LT Debt VS Equity VS FCFGLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

GLMD has a Current Ratio of 8.71. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.71, GLMD is in the better half of the industry, outperforming 76.40% of the companies in the same industry.
GLMD has a Quick Ratio of 8.71. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.71, GLMD is doing good in the industry, outperforming 76.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.71
Quick Ratio 8.71
GLMD Yearly Current Assets VS Current LiabilitesGLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

GLMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.85%, which is quite impressive.
EPS 1Y (TTM)74.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GLMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.74% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-152.71%
EPS Next 2Y15.81%
EPS Next 3Y17.45%
EPS Next 5Y20.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLMD Yearly Revenue VS EstimatesGLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2029 2030 10M 20M 30M 40M
GLMD Yearly EPS VS EstimatesGLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLMD. In the last year negative earnings were reported.
Also next year GLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLMD Price Earnings VS Forward Price EarningsGLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLMD Per share dataGLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as GLMD's earnings are expected to grow with 17.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.81%
EPS Next 3Y17.45%

More info and screens

0

5. Dividend

5.1 Amount

GLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (10/29/2025, 4:43:41 PM)

After market: 1.3882 +0.04 (+2.83%)

1.35

-0.12 (-8.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2025-08-28/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners1.42%
Inst Owner Change0%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap7.40M
Revenue(TTM)N/A
Net Income(TTM)-8722000
Analysts43.33
Price TargetN/A
Short Float %0.36%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.64%
Min EPS beat(2)25.58%
Max EPS beat(2)31.7%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-5.56
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS3.75
TBVpS3.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.01%
ROE -42.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.37%
ROA(5y)-66.75%
ROE(3y)-76.34%
ROE(5y)-80.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.71
Quick Ratio 8.71
Altman-Z -10.49
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.61%
EPS Next Y-152.71%
EPS Next 2Y15.81%
EPS Next 3Y17.45%
EPS Next 5Y20.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.42%
OCF growth 3YN/A
OCF growth 5YN/A

GALMED PHARMACEUTICALS LTD / GLMD FAQ

What is the fundamental rating for GLMD stock?

ChartMill assigns a fundamental rating of 2 / 10 to GLMD.


Can you provide the valuation status for GALMED PHARMACEUTICALS LTD?

ChartMill assigns a valuation rating of 0 / 10 to GALMED PHARMACEUTICALS LTD (GLMD). This can be considered as Overvalued.


How profitable is GALMED PHARMACEUTICALS LTD (GLMD) stock?

GALMED PHARMACEUTICALS LTD (GLMD) has a profitability rating of 1 / 10.


How financially healthy is GALMED PHARMACEUTICALS LTD?

The financial health rating of GALMED PHARMACEUTICALS LTD (GLMD) is 6 / 10.


Can you provide the expected EPS growth for GLMD stock?

The Earnings per Share (EPS) of GALMED PHARMACEUTICALS LTD (GLMD) is expected to decline by -152.71% in the next year.